• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthVaccines

RFK Jr. and his new vaccine committee are obsessing over thimerosal, a preservative antivaxxers have falsely tied to autism despite zero evidence of causation

By
Mike Stobbe
Mike Stobbe
,
Lauran Neergaard
Lauran Neergaard
and
The Associated Press
The Associated Press
By
Mike Stobbe
Mike Stobbe
,
Lauran Neergaard
Lauran Neergaard
and
The Associated Press
The Associated Press
June 26, 2025, 10:05 AM ET
RFK Jr. gesticulates in a hearing
HHS Secretary Robert F. Kennedy Jr., testifies during the House Energy and Commerce Subcommittee on Health hearing titled "The FY2026 Department of Health and Human Services Budget," in Rayburn building on Tuesday, June 24, 2025.Tom Williams / CQ-Roll Call, Inc—Getty Images

ATLANTA (AP) — U.S. Health Secretary Robert F. Kennedy Jr.’s new vaccine advisory committee backed another option to protect infants against a dangerous virus — before turning to questions about fall flu vaccines and a preservative in a small fraction of them that some antivaccine groups have falsely tied to autism.

Recommended Video

The Advisory Committee on Immunization Practices on Thursday took up protections against RSV, or respiratory syncytial virus, a common cause of cold-like symptoms that can dangerously inflame infants’ tiny airways.

In 2023, U.S. health officials began recommending two new measures to protect infants — a lab-made antibody for newborns and a vaccine for pregnant women — that experts say likely drove an improvement in infant mortality. That first antibody, called nirsevimab, proved to be 63% to 76% effective against emergency department visits for infants over the last year.

On Thursday, the vaccine panel voted 5-2 that another newly approved antibody shot, Merck’s clesrovimab, should be used similarly.

The ACIP, created more than 60 years ago, helps the Centers for Disease Control and Prevention determine who should be vaccinated against a long list of diseases, and when. Those recommendations have a big impact on whether insurance covers vaccinations and where they’re available.

Kennedy was a leading voice in the antivaccine movement before becoming the nation’s top health official. He fired the previous 17-member panel this month and replaced it with a seven-member group that includes several vaccine skeptics.

At its June meetings, the committee usually refreshes guidance for Americans 6 months and older to get a flu shot, and helps propel the annual fall vaccination campaign.

Presentations prepared for Thursday’s meeting suggest that the panel may do much the same this year. But there’s also a flu-related vote that promises controversy.

It concerns thimerosal, a form of mercury that’s been added to vaccines since the early 20th century to preventing bacterial contamination in multi-dose vials.

Kennedy has long held there was a tie between thimerosal and autism, and also accused the government of hiding the danger. Study after study has found no evidence that thimerosal causes autism. But since 2001, vaccines manufactured for the U.S. market and routinely recommended for children 6 years or younger have contained no thimerosal or only trace amounts, with limited exceptions.

Thimerosal was placed on the meeting agenda shortly after Kennedy’s new vaccine advisory was named last week.

Before the vote, the committee will hear from Lyn Redwood, the former president of what is now known as Children’s Health Defense — an antivaccine group founded by Kennedy.

Some public health experts contend the thimerosal discussion will unnecessarily raise doubt in vaccines while possibly also making them more expensive and harder to get this fall.

At the panel’s meeting Wednesday, Chrissie Juliano, executive director of the Big Cities Health Coalition, lamented the ouster of the former ACIP panel and the agenda of the new one.

Her organization, which represents large city health departments, “is deeply concerned that many routine vaccines may soon become inaccessible or unaffordable for millions of Americans if ACIP makes changes based on ideology rather than science,” she said. “The stakes are simply too high to let that happen.”

Fortune Brainstorm AI returns to San Francisco Dec. 8–9 to convene the smartest people we know—technologists, entrepreneurs, Fortune Global 500 executives, investors, policymakers, and the brilliant minds in between—to explore and interrogate the most pressing questions about AI at another pivotal moment. Register here.
About the Authors
By Mike Stobbe
See full bioRight Arrow Button Icon
By Lauran Neergaard
See full bioRight Arrow Button Icon
By The Associated Press
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.